Modality
Fusion Protein
MOA
EZH2i
Target
AHR
Pathway
mTOR
Thymoma
Development Pipeline
Preclinical
~Mar 2019
→ ~Jun 2020
Phase 1
~Sep 2020
→ ~Dec 2021
Phase 2
~Mar 2022
→ ~Jun 2023
Phase 3
Sep 2023
→ Mar 2030
Phase 3Current
NCT08193313
680 pts·Thymoma
2023-09→2030-03·Active
680 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-01-073mo agoConference· Thymoma
2030-03-083.9y awayPh3 Readout· Thymoma
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P3
Active
Catalysts
Conference
2026-01-07 · 3mo ago
Thymoma
Ph3 Readout
2030-03-08 · 3.9y away
Thymoma
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08193313 | Phase 3 | Thymoma | Active | 680 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR |